Yancey Holmes, MD
Endocrinology, Diabetes & Metabolism · Covington, KYNPI 1932177235
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $133,711 of the $148,198 with a category attached, or 90.2%. Novo Nordisk accounts for 67.0% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $82,191 and has fallen 99.0% since, to $842 in 2025. Among endocrinology, diabetes & metabolism clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 513 payments — averaging $288.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$99K
- AstraZeneca$31K
- Abbott$7K
- Tandem Diabetes Care, Inc.$6K
- Dexcom, Inc.$799
- Medtronic$603
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$133,71190%
- Travel & lodging$5,6564%
- Food & beverage$8,4826%
- Education$3490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 180 | $99,297 |
| AstraZeneca(2 entities) | 41 | $30,824 |
| Abbott | 19 | $7,042 |
| Tandem Diabetes Care, Inc. | 24 | $6,206 |
| Dexcom, Inc. | 29 | $799 |
| Medtronic(2 entities) | 21 | $603 |
| Corcept Therapeutics | 13 | $420 |
| Amgen(2 entities) | 20 | $336 |
| AbbVie | 16 | $260 |
| Lilly USA, LLC | 15 | $236 |
| Sanofi-aventis U.S. LLC | 11 | $208 |
| Xeris Pharmaceuticals, Inc. | 12 | $185 |
| Tolmar, Inc. | 24 | $181 |
| Pfizer | 12 | $180 |
| Amarin Pharma, Inc. | 10 | $172 |
| Mannkind Corporation | 7 | $141 |
| Sequel Med Tech, LLC | 1 | $139 |
| Boehringer Ingelheim | 7 | $113 |
| Bayer | 6 | $98 |
| Recordati_rare_diseases_inc. | 6 | $97 |
| Lifescan, Inc. | 5 | $82 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| Shire North American Group Inc | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| BD | 2 | $45 |
| IBSA Pharma Inc. | 3 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Insulet Corporation | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Novartis | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| EUSA Pharma (US) LLC | 2 | $27 |
| Clarus Therapeutics Inc. | 2 | $20 |
| Radius Health, Inc. | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Vivus LLC | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$36,271
- RYBELSUS$32,891
- FARXIGA$30,422
- Tresiba$23,183
- FreeStyle Libre Pro$6,588
- Xultophy 100/3.6$3,650
- t:slim X2 insulin pump$3,200
- t-slim insulin pump$2,900
- FreeStyle Libre 2$322
- Korlym$227
- InPen$141
- TWIIST$139
- Minimed 670G System$139
How this compares
$148,198 in reported general payments places this provider in the 90th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 691 | $860,809 |
| FarxigaDapagliflozin Propanediol | 383 | $412,287 |
| MounjaroTirzepatide | 262 | $351,366 |
| JardianceEmpagliflozin | 291 | $322,435 |
| TrulicityDulaglutide | 139 | $239,573 |
| Tresiba Flextouch U-100Insulin Degludec | 226 | $158,783 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 112 | $125,450 |
| Xigduo XrDapaglifloz Propaned/Metformin | 122 | $113,820 |
| Tresiba Flextouch U-200Insulin Degludec | 88 | $109,920 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 91 | $90,695 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 38 | $73,771 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 112 | $65,298 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $62,363 |
| RybelsusSemaglutide | 42 | $61,005 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 333 | $50,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $99,297 | $934,254761 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $236 | $610,830449 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $113 | $460,197419 claims |
| AstraZenecaFarxiga | $30,824 | $412,287383 claims |
| BayerKerendia | $98 | $18,41821 claims |
| AbbVieSynthroid | $260 | $11,511161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Covington
- Wael EidCovington$31K
- Linda HermillerCovington$12K
- Jaspreet ChahalCovington$11K
- Ailleen Heras HerzigCovington$5K
- Irina KorablevaCovington$4K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.